No Result
View All Result
  • Private Data
  • Membership options
  • Login
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHubHOT
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Subscribe
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHubHOT
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Home DISTRESSED ASSETS

Rescuing drugs: Ignota Labs raises €6.6 million to turn around failed drugs

EU Startupsby EU Startups
February 26, 2025
Reading Time: 3 mins read
in DISTRESSED ASSETS, UK&IRELAND
Share on FacebookShare on Twitter

London-based Ignota Labs, an AI-driven drug turnaround company, today announced the close of a €6.6 million Seed funding round, to advance into early-stage clinical trials of their first asset, a PDE9A inhibitor.

The round was co-led by Montage Ventures and AIX Ventures with participation from Modi Ventures, Blue Wire Capital, and Gaingels.

“We’re thrilled to have the support of this leading investor syndicate in our mission to rescue promising yet struggling drugs with our technology,” said Sam Windsor, CEO and Co-founder, Ignota Labs. “Traditional safety assessments reveal when something is wrong, but our platform goes a step further by identifying the exact molecular and biological issues to provide actionable insights to re-engineer and revive therapies. With this funding, we can expand our efforts to salvage distressed assets and accelerate the delivery of life-saving therapies to patients.”

Founded in 2021 by Sam Windsor, Dr Layla Hosseini-Gerami, and Dr Jordan Lane, Ignota Labs specialises in rescuing promising but failing drugs.

CEO Sam Windsor previously worked on DeepMind’s AlphaFold team and has a decade of experience in life sciences. Chief Scientific Officer Jordan Lane has advanced five assets to clinical development, and Chief Data Science Officer Layla Hosseini-Gerami is an expert on AI and cheminformatics.

According to Ignota Labs, more than half of all clinical trials fail due to safety issues, preventing over 56% of drugs from reaching patients and resulting in a €381.5 billion annual loss.

Their proprietary platform, SAFEPATH, uses deep learning to address these challenges by uncovering the mechanisms behind drug toxicity. Instead of identifying what went wrong, their AI platform combines cheminformatics, bioinformatics, and multimodal data analysis to explain why and how safety issues occur, delivering actionable insights to refine or repurpose drug candidates.

The company identifies promising drug candidates that have been abandoned due to safety concerns – typically 80-90% of the way to success – and uses SAFEPATH to determine the underlying issues and develop solutions.

“Ignota Labs is solving one of the most critical challenges in drug development, rescuing promising therapies that would otherwise be abandoned due to safety issues,” said Todd Kimmel, Founder and Managing Partner, Montage Ventures. “Their SAFEPATH platform represents a groundbreaking approach, combining cutting-edge AI with deep scientific expertise to address the root causes of drug toxicity. We believe Ignota Labs has the ability to enable more drugs to make it to the clinic and get to the patients who need them.”

“Ignota is redefining drug development and pioneering a new era of predictive and engineerable biology—where AI systematically de-risks therapeutic development by designing safer, more effective drugs with precision,” said Krish Ramadurai, Partner at AIX Ventures. “Their approach shifts biopharmaceutical R&D from trial-and-error to a rational, data-driven process, enabling molecules to be precisely refined at scale to accelerate clinical development. I’m incredibly excited about their potential to transform AI-driven drug discovery and unlock massive value from previously failed assets to improve patient outcomes.”

The company successfully in-licensed its first asset, a first-in-class metabolic health drug with the potential to improve the lives of over 1.2 billion post-menopausal women. Using SAFEPATH, Ignota Labs resolved safety concerns that halted the drug’s progress, validating its findings through rodent models.

Read the orginal article: https://www.eu-startups.com/2025/02/rescuing-drugs-ignota-labs-raises-e6-6-million-to-turn-around-failed-drugs/

Gateways to Italy

Gateways to Italy – Offer your services to funds and investors willing to explore opportunities in Italy. Become a partner!

Gateways to Italy – Offer your services to funds and investors willing to explore opportunities in Italy. Become a partner!

by Partner
June 6, 2023

Sign up to our newsletter

SIGN UP

Related Posts

GREEN

Ofgem approves £24bn in transmission upgrades in boost to UK’s AI ambitions

July 4, 2025
PRIVATE DEBT

MOGOPLUS Raises $1.5m to Scale Agentic AI in Lending and Open Data Markets

July 4, 2025
FINTECH

Can Europe catch up? Why the EU is still behind in the global AI race

July 4, 2025

ItaHub

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

November 4, 2024
Italy’s SMEs export toward 260 bn euros in 2025

Italy’s SMEs export toward 260 bn euros in 2025

September 9, 2024
With two months to go before the NPL Directive, in Italy the securitization rebus is still to be unraveled

With two months to go before the NPL Directive, in Italy the securitization rebus is still to be unraveled

April 23, 2024
EU’s AI Act, like previous rules on technology,  looks more defensive than investment-oriented

EU’s AI Act, like previous rules on technology, looks more defensive than investment-oriented

January 9, 2024

Co-sponsor

Premium

Funds vying for management consulting firm BIP, a CVC portfolio company. All deals in the sector

Funds vying for management consulting firm BIP, a CVC portfolio company. All deals in the sector

March 6, 2025
Private equity, Italy 2024 closes with 588 deals as for investments and divestments from 549 in 2023. Here is the new BeBeez’s report

Private equity, Italy 2024 closes with 588 deals as for investments and divestments from 549 in 2023. Here is the new BeBeez’s report

February 10, 2025
Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

November 4, 2024
Venture capital investments top €1.3bn in 208 rounds as of Sep30  in Italy. They were €1.5 in all 2023. The new BeBeez Report

Venture capital investments top €1.3bn in 208 rounds as of Sep30 in Italy. They were €1.5 in all 2023. The new BeBeez Report

October 28, 2024
Next Post

Zopa reveals plans for new HQ in London's Canary Wharf

Gap between prices of houses and flats ‘at highest point in 30 years’

EdiBeez srl

C.so Italia 22 - 20122 - Milano
C.F. | P.IVA 09375120962
Aut. Trib. Milano n. 102
del 3 aprile 2013

COUNTRY

Italy
Iberia
France
UK&Ireland
Benelux
DACH
Scandinavia&Baltics

CATEGORY

Private Equity
Venture Capital
Private Debt
Distressed Assets
Real Estate
Fintech
Green

PREMIUM

ItaHUB
Legal
Tax
Trend
Report
Insight view

WHO WE ARE

About Us
Media Partnerships
Contact

INFORMATION

Privacy Policy
Terms&Conditions
Cookie Police

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHub
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Subscribe
  • Login
  • Cart